|
|
|
|
Vol. 57, Issue 4, 784-791, April 2000
Confer Resistance to Amsacrine: Relevance for Antitumor Drug Resistance
in Human Cells1
Molecular Genetics Group, Department of Biochemistry, St. George's
Hospital Medical School, University of London, London, United Kingdom
Human topoisomerase II, a nuclear protein involved in chromosome
segregation, is the target of amsacrine and other clinically important
anticancer drugs. The enzyme is expressed as
and
isoforms whose
mutation/down-regulation has been implicated in drug resistance. To
understand the role of target mutations in cellular drug resistance, we
have used yeast to select and characterize plasmid-borne human
topoisomerase II
mutants resistant to amsacrine. Single point
changes of Glu571 to Lys (E571K) or Arg486 to Lys (R486K) in the
conserved PLRGK motif, both of which reside in the GyrB homology domain
of human topoisomerase II
, were frequently selected and could be
shown in vivo to confer >25-fold and >100-fold resistance,
respectively, to amsacrine and ~3-fold cross-resistance to etoposide.
Highly purified E571K and R486K human topoisomerase II
proteins
required 100-fold higher levels of amsacrine to induce DNA cleavage
similar to that of wild-type protein, consistent with a resistance
mechanism involving reduced cleavable complex formation. Our functional
studies of the R486K mutation, previously identified in two
amsacrine-resistant human cell lines and in human biopsy material,
establish unequivocally that it confers resistance, and suggest
mechanisms for its phenotypic expression in vivo. These results differ
significantly from previous work using yeast topoisomerase II as a
model system: introduction of the equivalent mutation to R486K (R476K)
into the yeast enzyme did not give amsacrine resistance. We conclude
that species-specific differences in topoisomerase II enzymes can
affect the drug resistance phenotype of particular mutations and
highlight the need to study the relevant human homolog.
This article has been cited by other articles:
![]() |
C. Leontiou, G. P. Watters, K. L. Gilroy, P. Heslop, I. G. Cowell, K. Craig, R. N. Lightowlers, J. H. Lakey, and C. A. Austin Differential Selection of Acridine Resistance Mutations in Human DNA Topoisomerase IIbeta Is Dependent on the Acridine Structure Mol. Pharmacol., April 1, 2007; 71(4): 1006 - 1014. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Gilroy, C. Leontiou, K. Padget, J. H. Lakey, and C. A. Austin mAMSA resistant human topoisomerase II{beta} mutation G465D has reduced ATP hydrolysis activity Nucleic Acids Res., March 20, 2006; 34(5): 1597 - 1607. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Leontiou, J. H. Lakey, R. Lightowlers, R. M. Turnbull, and C. A. Austin Mutation P732L in Human DNA Topoisomerase IIbeta Abolishes DNA Cleavage in the Presence of Calcium and Confers Drug Resistance Mol. Pharmacol., January 1, 2006; 69(1): 130 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Leontiou, J. H. Lakey, and C. A. Austin Mutation E522K in Human DNA Topoisomerase II{beta} Confers Resistance to Methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and Methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but Hypersensitivity to Etoposide Mol. Pharmacol., September 1, 2004; 66(3): 430 - 439. [Abstract] [Full Text] [PDF] |
||||